Genomic Vision: Postponement of the ordinary general meeting of shareholders of June 28, 2022

BAGNEUX, France, June 27, 2022–(BUSINESSWIRE)–Regulatory News: Genomic Vision (FR0011799907 – GV, PEA-PME eligible – the “Company”) (Paris:GV)a biotechnology company that develops tools and services dedicated to the analysis and control of genome modifications, informs its shareholders that, in view of the requests for admission cards, postal voting forms and proxies received at today by the … Read more

Genomic Vision obtains the renewal of its ISO 13485: 2016 certification

BAGNEUX, France, June 23, 2022–(BUSINESS WIRE)–Regulatory News: GENOMIC VISION (FR0011799907 – GV, PEA-PME eligible) (Paris:GV). As part of compliance with the cycle of its certification to the ISO 13485: 2016 standard by the GMED of the LNE group, an independent French organization Notified by the National Agency for the Safety of Medicines and Health Products … Read more

Genomic Vision obtains a new patent for its “Physical Characterization of Telomeres” technique based on molecular combing

BAGNEUX, France, June 16, 2022–(BUSINESS WIRE)–Regulatory News: Genomic Vision (FR0011799907 – GV, PEA-PME eligible) (Paris:GV)a biotechnology company that develops tools and services dedicated to the analysis and control of genome modifications, announces today the successful publication of the patent on the “Physical Characterization of Telomeres” (PCT). The patent was granted by the United States Patent … Read more

Genomic Vision: Availability of preparatory documents and procedures for participation and voting at the extraordinary general meeting of shareholders of May 23, 2022

BAGNEUX, France, May 02, 2022–(BUSINESSWIRE)–Regulatory News: Genomic Vision (FR0011799907 – GV, PEA-PME eligible) (Paris:GV)a biotechnology company that develops tools and services dedicated to the analysis and control of genome modifications, announces today the availability of the preparatory documents for its extraordinary general meeting to be held on May 23, 2022 at 2 p.m. company headquarters. … Read more

Génome Québec and Université Laval launch Genovalia, the first center for the valorization of non-human genomic data in Québec

Genome Quebec and Universite Laval launch Genovalia the first center

On April 12, Génome Québec and Université Laval announced the launch of Genovalia, the first center for the production, processing and enhancement of non-human genomic data in Québec. This center will aim to support work in genomics, from the pre-project planning to the development, structuring and storage of data by applying FAIR principles for data … Read more

Genomic Vision: Availability of the universal registration document

Genomic Vision Availability of the universal registration document

BAGNEUX, France, April 15, 2022–(BUSINESS WIRE)–Regulatory News: Genomic Vision (FR0011799907 – GV, PEA-PME eligible) (Paris:GV), a biotechnology company that develops tools and services dedicated to the analysis and control of genome modifications, announces today that it has made available to the public and filed with the Autorité des marchés financiers its universal registration document for … Read more